These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23588793)

  • 21. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacology of ergotamine and dihydroergotamine.
    Silberstein SD
    Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ergotamine, dihydroergotamine: current uses and problems.
    Tfelt-Hansen P
    Curr Med Res Opin; 2001; 17 Suppl 1():s30-4. PubMed ID: 12463275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
    Pradalier A; Guérard des Lauriers A; Scheck F; Peraudeau P; Lacoste JP; Cajfinger F
    Pathol Biol (Paris); 1995 Nov; 43(9):806-13. PubMed ID: 8746103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
    Tfelt-Hansen P
    Headache; 2014 Feb; 54(2):383. PubMed ID: 24512579
    [No Abstract]   [Full Text] [Related]  

  • 30. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.
    Scott AK
    Clin Neuropharmacol; 1992 Aug; 15(4):289-96. PubMed ID: 1516074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications.
    Kelley NE; Tepper DE
    Headache; 2012 Mar; 52(3):467-82. PubMed ID: 22404708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute treatment of paediatric migraine: a meta-analysis of efficacy.
    Silver S; Gano D; Gerretsen P
    J Paediatr Child Health; 2008 Jan; 44(1-2):3-9. PubMed ID: 17854415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
    Kayser V; Aubel B; Hamon M; Bourgoin S
    Br J Pharmacol; 2002 Dec; 137(8):1287-97. PubMed ID: 12466238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
    Schaerlinger B; Hickel P; Etienne N; Guesnier L; Maroteaux L
    Br J Pharmacol; 2003 Sep; 140(2):277-84. PubMed ID: 12970106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of transformed refractory migraine with intravenous dihydroergotamine].
    Cid C; Ortega-Valín F; Valero M; Muñoz R; Pascual J
    Neurologia; 1999; 14(6):315-8. PubMed ID: 10439626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.
    Dahlöf C; Maassen Van Den Brink A
    Headache; 2012 Apr; 52(4):707-14. PubMed ID: 22444161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ergotamine and dihydroergotamine: a review.
    Bigal ME; Tepper SJ
    Curr Pain Headache Rep; 2003 Feb; 7(1):55-62. PubMed ID: 12525272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hospital management of severe migrainous headache.
    Jauslin P; Goadsby PJ; Lance JW
    Headache; 1991 Nov; 31(10):658-60. PubMed ID: 1663091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward.
    Tfelt-Hansen PC; Koehler PJ
    Cephalalgia; 2008 Aug; 28(8):877-86. PubMed ID: 18460007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
    Saper JR; Silberstein S
    Headache; 2006 Nov; 46 Suppl 4():S171-81. PubMed ID: 17078849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.